Overview

Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of olanzapine in the long-term treatment for patients with bipolar I disorder, depressed.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine